ValuEngine upgraded shares of NantKwest, Inc. (NASDAQ:NK) from a strong sell rating to a sell rating in a report issued on Wednesday.

A number of other analysts have also weighed in on NK. Zacks Investment Research raised shares of NantKwest from a hold rating to a buy rating and set a $4.25 price objective for the company in a research note on Thursday, June 1st. FBR & Co reaffirmed an outperform rating and issued a $9.00 price objective (down from $22.00) on shares of NantKwest in a research note on Friday, March 17th. Citigroup Inc. lowered shares of NantKwest from a neutral rating to a sell rating and set a $3.00 price objective for the company. in a research note on Monday, May 15th. Finally, Jefferies Group LLC set a $4.00 price objective on shares of NantKwest and gave the stock a hold rating in a research note on Monday, May 8th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the stock. The stock has an average rating of Hold and a consensus price target of $10.21.

Shares of NantKwest (NK) opened at 7.08 on Wednesday. The stock’s market cap is $581.66 million. The firm’s 50-day moving average is $4.07 and its 200 day moving average is $4.67. NantKwest has a 12 month low of $2.71 and a 12 month high of $9.60.

COPYRIGHT VIOLATION NOTICE: “NantKwest, Inc. (NK) Upgraded to Sell by ValuEngine” was posted by Daily Political and is owned by of Daily Political. If you are viewing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright laws. The original version of this report can be viewed at https://www.dailypolitical.com/2017/06/20/nantkwest-inc-nk-upgraded-to-sell-by-valuengine.html.

Hedge funds have recently added to or reduced their stakes in the stock. Geode Capital Management LLC raised its stake in NantKwest by 7.9% in the first quarter. Geode Capital Management LLC now owns 256,699 shares of the biotechnology company’s stock valued at $911,000 after buying an additional 18,685 shares during the last quarter. Vanguard Group Inc. raised its stake in NantKwest by 8.4% in the first quarter. Vanguard Group Inc. now owns 2,082,706 shares of the biotechnology company’s stock valued at $7,394,000 after buying an additional 160,510 shares during the last quarter. Alliancebernstein L.P. raised its stake in NantKwest by 8.7% in the first quarter. Alliancebernstein L.P. now owns 33,800 shares of the biotechnology company’s stock valued at $120,000 after buying an additional 2,700 shares during the last quarter. Dynamic Technology Lab Private Ltd raised its stake in NantKwest by 53.4% in the first quarter. Dynamic Technology Lab Private Ltd now owns 32,939 shares of the biotechnology company’s stock valued at $117,000 after buying an additional 11,465 shares during the last quarter. Finally, Vident Investment Advisory LLC raised its stake in NantKwest by 20.0% in the first quarter. Vident Investment Advisory LLC now owns 138,691 shares of the biotechnology company’s stock valued at $492,000 after buying an additional 23,112 shares during the last quarter. 19.80% of the stock is owned by institutional investors and hedge funds.

NantKwest Company Profile

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for NantKwest Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantKwest Inc. and related companies with MarketBeat.com's FREE daily email newsletter.